Shimada K, Tabuse K, Kono N, Katsumi M, Yamamoto H, Yamamoto Y, Endo A
Gan To Kagaku Ryoho. 1983 Aug;10(8):1844-9.
The clinical effect of intratumoral administration of OK-432 was evaluated. The patients with nonresectable advanced cancer were divided into three groups according to administration method of OK-432 at laparotomy: Group I; Intratumoral administration, Group II; Scattering to the abdominal cavity, and Group III; No OK-432, administration. Improvement in suppression of tumor progression was more frequently noticed in the Group I compared to the Group II and III, but there was no significant difference in terms of survival time and rate among the three groups.
评估了瘤内注射OK-432的临床效果。将不可切除的晚期癌症患者在剖腹手术时根据OK-432的给药方法分为三组：第一组；瘤内注射，第二组；腹腔内散注，第三组；不注射OK-432。与第二组和第三组相比，第一组更常观察到肿瘤进展抑制的改善，但三组之间在生存时间和生存率方面没有显著差异。
